Your session is about to expire
← Back to Search
PD-1 Blockade + Dendritic Cell Fusion Vaccine + CT-011 for Multiple Myeloma
Study Summary
This trial is testing the safety of CT-011 and the combination of the Dendritic cell fusion vaccine and CT-011 after ASCT in patients with multiple myeloma. They are also testing to see if the combination is more successful in preventing or delaying the disease from coming back, compared to treatment with ASCT alone.
- Multiple Myeloma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your heart's pumping ability is greater than 45%.Your test results need to match the study's requirements.You have had a serious blood clot in a vein in the past.You have a serious autoimmune disease.You have HIV.You have a serious illness like a severe infection needing IV antibiotics, or a major heart condition with significant heart rhythm problems, heart artery blockages, or heart failure.You have had a bone marrow or stem cell transplant from someone else.Patients with multiple myeloma who may be considered for intensive chemotherapy followed by stem cell transplant.You are in good enough health to carry out daily activities and have a life expectancy of more than nine weeks.You have more than 20% of your bone marrow affected by plasmacytoma that can be removed with local anesthesia.You cannot have any active or past autoimmune diseases like Type I diabetes, Type II diabetes, vitiligo, or stable hypothyroidism.You have a history of an elevated M component in your blood or urine.Your lung function is good, with a DLCO (adjusted) of more than 50%.
- Group 1: Group 1
- Group 2: Group 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the research team recruiting for this clinical experiment?
"This trial is no longer accepting participants. It was first posted on March 1st 2010, and the most recent amendment to it took place on September 5th 2022. Currently there are 807 studies seeking patients with multiple myeloma and one study searching for Group 2 subjects."
Is Group 2 a viable option for patients with regards to safety?
"Group 2's safety was evaluated and assessed as a score of 2, given that there is existing data validating its security but none currently affirming its efficacy."
Are there any opportunities for participants to join this experiment?
"Unfortunately, this medical study is no longer enrolling patients. Initially posted on March 1st 2010 and last edited September 5th 2022, any prospective participants are encouraged to check out the 807 studies actively searching for individuals with multiple myeloma or the single trial looking for Group 2 applicants."
Could you provide me with an overview of the other experiments carried out in relation to Group 2?
"At the current moment, only 1 research project concerning Group 2 is active with 0 Phase 3 trials. These studies are mainly held in Boston but also span to other locations."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger